The pharma stock gained after its subsidiary launched the first FDA-approved generics of phenylpropanolamine and furosemide tablets for veterinary use. Strong Q1FY26 results, robust pipeline, and steady guidance with 30+ launches and >26% margins highlight sustained growth momentum across domestic and international markets
The shares of the prominent pharmaceutical company gained up to 1 percent in today’s trading session after the company’s subsidiary launched the first FDA-approved generic of phenylpropanolamine hydrochloride tablets.
With a market capitalization of Rs 1,04,462.18 crore, the shares of Zydus Lifesciences Ltd were trading at Rs 1038.15 per share, increasing around 0.28 percent as compared to the previous closing price of Rs 1,036.70 apiece.
FDA Launch
The shares of Zydus Lifesciences Ltd have seen positive movement after ZyVet Animal Health, a wholly owned subsidiary of Zydus Pharmaceuticals (USA) Inc, has launched the first FDA-approved generic of phenylpropanolamine hydrochloride tablets.
Phenylpropanolamine hydrochloride is widely used to manage urinary incontinence in dogs, particularly spayed females and older pets affected by urethral sphincter hypotonus. ZyVet’s generic offers reliable relief, multiple dosage strengths for accurate treatment, and improved compliance, making it a practical solution for veterinarians and pet owners seeking long-term management.
Additionally, ZyVet has announced the launch of the first veterinary-approved generic of Furosemide tablets, a critical therapy for managing congestive heart failure and chronic fluid retention in dogs and cats.
Moreover, Furosemide continues to be the leading veterinary diuretic for managing edema and pulmonary congestion linked to cardiac, renal, or systemic diseases. ZyVet’s formulation enhances treatment by providing a reliable, affordable option that ensures dosing flexibility and consistent availability, making it suitable for long-term veterinary therapy.
Also read: Smallcap stock jumps over 4% after receiving ₹80 Cr order from Tata Steel
Financial & Operational Highlights
The company posted steady growth in Q1FY26, with revenue rising 6% to Rs 6,574 crore from Rs 6,208 crore in Q1FY25. Net profit grew 3% to Rs 1,521 crore versus Rs 1,482 crore a year earlier, reflecting resilient demand and improved operations despite moderate margin expansion.
The pipeline highlights strong growth prospects with multiple launches ahead. Sitagliptin is commercialized, while Docetaxel and two more drugs are set for near-term rollout. Generic Ibrance could launch by FY27/FY28, offering a large opportunity. Desidustat approval in China is expected in 12 months, CUTX-101 in FY26, and Amplitude Surgical’s robotic arm launch in FY26, strengthen future revenue visibility.
The company’s outlook remains steady with single-digit US revenue growth in FY26, supported by 30+ launches and a strong 505(b)(2) pipeline for medium-term momentum. EBITDA margin guidance is firm above 26%. International markets are expected to grow in the high teens to mid-twenties, while FY26 capex is pegged at Rs 1,200 crore with no major US facility spend.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
